Mazdutide

Mazdutide is a dual GLP-1 and glucagon receptor agonist currently in Phase 3 trials for obesity, where it is primarily utilized by the community for weight loss and appetite suppression. Users typically run doses ranging from 100 µg to 12 mg, with 1 mg being the most common daily amount, though specific timing and cycling protocols remain inconsistent across reports. Readers should note that the evidence base for off-label indications is significantly thinner than the current discourse suggests, as most exploratory research lacks published results, and there is no insurance pathway for access outside of the obesity indication.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.62.82.73.23.12.0

Research Evidence

Evidence shape

Mazdutide carries moderate clinical evidence, supported by 14 published human studies primarily focused on obesity and weight management. While the research includes Phase 3 trials and demonstrates measurable weight reduction, the broader clinical landscape remains thin; of the 41 registered trials, only one has posted results, with the vast majority of the 28 mapped indications existing as single-trial, exploratory investigations. This reliance on a single blinded study with results indicates that while the peptide is actively moving through the pipeline, most of its potential therapeutic applications lack the depth of published, peer-reviewed data.

Depthhow much
42 registered trials
19 completed · 1 with posted results · 22 recruiting / active · combined n=179
Breadthhow many areas
29 indications mapped
1 with results · 27 thin / exploratory · 1 animal-only · 22 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
1 blinded with results · 3 distinct sponsors · AE table from NCT06124807 · 11 linked publications on registered trials
Breadth and depth57 rows captured
Human
direct clinical signal
56
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

Mazdutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
High Purity Peptides
Hong Kong
100 mg×10
$170.00
$1.7/mg
2
Uther
unknown
100 mg×10
$260.00
$2.6/mg
3
Bulk Peptide Supply
unknown
100 mg×10
$300.00
$3/mg
4
Happy Peps
US
10 mg
$45.00
$4.5/mg
5
Edge Peptides
International
100 mg×10
$485.00
$4.85/mg
6
Peptide Powerhouse
US
10 mg
$59.00
$5.9/mg

price offers can be sorted by column · 5 out-of-stock offers not shown

1-6 of 34

Mazdutide dosing & protocol

How Mazdutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 31
Typical dose
4 mg2 mg – 9 mg
typical
0
5 mg
10 mg
15 mg
distribution of 20 reported doses · darker = more
Frequency
weekly
Route
subQ

Mazdutide was administered subcutaneously at a typical dose of 4 mg once weekly in research trials, with individual studies using amounts between 2 mg and 9 mg per week.

31 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
5 mg
10 mg
15 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 21
Typical dose
1 mg100 µg – 12 mg
typical
0
5 mg
10 mg
15 mg
distribution of 25 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community users typically dose Mazdutide at about 1 mg, with reported amounts spanning 0.6 mg up to 9 mg per week; weekly injections are the most frequently mentioned schedule, while a few users give a single dose without specifying frequency. No cycling patterns were reported.

21 sources

Related peptides

SemaglutideTirzepatideRetatrutideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensine